Walgreens posts loss on $6.5 billion opioid litigation cost By Reuters

(Reuters) – Drugstore chain Walgreens Boots Alliance (NASDAQ:) Inc reported a internet quarterly loss on Thursday because it took a $6.5 billion opioid litigation cost, sending its shares down almost 2% in premarket commerce.

Walgreens and rivals CVS Well being Corp (NYSE:) and Walmart (NYSE:) Inc in November final yr agreed to pay about $13.8 billion to resolve 1000’s of U.S. state and native lawsuits accusing the pharmacy chains of mishandling opioid ache medicine.

Walgreens, which had been counting on positive aspects from administering COVID-19 vaccines to tide over losses from low prescription volumes because of the pandemic, has seen demand for the pictures fall in current quarters.

The corporate in October mentioned it anticipated prescription volumes to get well in 2023 however warned that “decrease COVID exercise would proceed to be a sizeable headwind”.

It administered about 8 million vaccines within the first quarter, which noticed pharmacy gross sales drop about 4% at the same time as demand for cough and chilly medicine has been excessive amid one of many worst U.S. flu seasons in a decade.

Walgreens reaffirmed its 2023 adjusted revenue forecast of $4.45 per share to $4.65 per share.

Internet loss attributable to Walgreens was $3.72 billion, or $4.31 per share, for the quarter ended Nov. 30, in contrast with a revenue of $3.58 billion, or $4.13 per share, a yr earlier together with a one-time acquire of $2.5 billion.

Excluding gadgets, the corporate earned $1.16 per share within the first quarter, above Refinitiv IBES estimates of $1.14 a share.